Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating activities
Net loss	$ (225,304)	$ (200,368)	$ (207,298)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	20,532	19,221	12,254
Noncash lease expense	6,920	7,227	7,028
Share-based compensation expense	62,908	55,477	43,251
Intangible assets amortization	1,699	1,699	1,699
Investment amortization	(9,184)	741	7,233
Impairment of right-of-use and related long-lived assets	25,429
Inventory reserve	1,387	2,638
Noncash interest expense	5,300	985
Other	172	(19)	(78)
Changes in operating assets and liabilities
Accounts receivable, net	2,032	(22,648)	(7,362)
Inventory	(2,838)	817	(5,200)
Prepaid expenses and other current assets	(1,930)	3,551	1,286
Accounts payable and accrued liabilities	(5,407)	7,111	3,940
Operating lease right-of-use assets and liabilities	(8,676)	(4,050)	8,522
Deferred revenue	(29,291)	(56,496)	(57,727)
Other	(73)	169	(275)
Net cash used in operating activities	(156,324)	(183,945)	(192,727)
Investing activities
Purchases of property and equipment	(10,697)	(16,349)	(61,746)
Purchases of marketable securities	(429,558)	(278,778)	(316,544)
Proceeds from maturities of marketable securities	569,902	298,032	559,500
Net cash provided by investing activities	129,647	2,905	181,210
Financing activities
Proceeds from exercise of stock options	2,245	7,890	26,717
Proceeds from revenue interest purchase agreement, net of issuance costs		124,375
Proceeds from initial capital contributions for Digital Biotechnologies, Inc.			429
Net cash provided by financing activities	2,245	132,265	27,146
Net (decrease) increase in cash, cash equivalents and restricted cash	(24,432)	(48,775)	15,629
Cash, cash equivalents and restricted cash at beginning of year	92,428	141,203	125,574
Cash, cash equivalents and restricted cash at end of year	67,996	92,428	141,203
Noncash investing activities
Purchases of equipment included in accounts payable and accrued liabilities	687	1,719	$ 682
Supplemental disclosure of cash flow information
Cash paid for interest	$ 8,985	$ 494